Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04269200
Title Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca

endometrial carcinoma



Durvalumab + Olaparib

Carboplatin + Durvalumab + Paclitaxel

Carboplatin + Durvalumab + Olaparib + Paclitaxel

Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | ESP | DEU | CAN | BEL

No variant requirements are available.